The True Cost of Lyme Disease: A Growing Economic Burden

Lyme disease carries a significant cost—not only to individual patients, but to society as a whole. When persistent symptoms develop, the financial impact rises sharply. :contentReference[oaicite:0]{index=0}

Cost of Early vs Chronic Lyme Disease

For patients with early Lyme disease, the average annual cost is relatively modest:

• Direct medical costs: $801
• Indirect medical costs: $259
• Non-medical costs: $52
• Productivity losses: $196

Total: approximately $1,300 per patient

However, the cost increases dramatically for patients with chronic or persistent symptoms:

• Direct medical costs: $1,872
• Indirect medical costs: $434
• Non-medical costs: $5,109
• Productivity losses: $8,785

Total: approximately $16,199 per patient annually

The cost of chronic Lyme disease exceeds that of several other common chronic illnesses, including rheumatoid arthritis, fibromyalgia, and lupus.

Persistent Symptoms Add to the Burden

Persistent symptoms are not uncommon.

In one study, 36% of patients treated for early Lyme disease developed Post-Treatment Lyme Disease Syndrome (PTLDS).

At 6 months:

• 36% reported fatigue
• 20% reported widespread pain
• 45% reported cognitive difficulties

Patients with PTLDS had significantly reduced quality of life compared to those who recovered fully.

National Economic Impact

Earlier estimates based on reported cases suggested an annual cost of approximately $203 million.

However, with current estimates of at least 300,000 cases per year, the economic burden is likely much higher.

Using available data:

• Early Lyme disease: ~192,000 cases × $1,310 ≈ $251 million
• Chronic/persistent Lyme disease: ~108,000 cases × $16,199 ≈ $1.75 billion

Total estimated annual cost: approximately $2 billion

What These Estimates May Miss

These figures likely underestimate the true burden.

• Long-term illness beyond the study period is not fully captured
• Patients with symptoms lasting decades are not included
• Pain and suffering are not quantified

In one long-term study, 11% of patients continued to experience PTLDS more than a decade after treatment.

Clinical Perspective

The financial impact of Lyme disease reflects the clinical challenges associated with persistent symptoms.

When a significant proportion of patients remain symptomatic, the cost extends beyond initial treatment.

Improved strategies for early diagnosis, treatment, and management of persistent symptoms may help reduce both individual and societal burden.

Patients may benefit from understanding persistent symptoms, reviewing treatment variability, and considering coinfections when recovery is incomplete.

Key Takeaway

Lyme disease is not only a medical condition—it is a significant and growing economic burden.

Addressing persistent symptoms may be an important step in reducing both patient suffering and long-term costs.

References

1. Zhang X et al. Emerg Infect Dis. 2006.
2. Aucott JN et al. Qual Life Res. 2013.
3. Weitzner E et al. Diagn Microbiol Infect Dis. 2016.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention